

These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling.

Drug Details

Company Name	Business Partner	Drug Name	Generic Name	Unique ID	Studied Indications or Disease	Phase
Abbott Laboratories		Zemplar Injection	Paricalcitol	2001022	Hyperparathyroidism, Secondary	Phase IV
Clinical Study Summary	<p>Protocol No. 2001022: A Phase 4, Double-Blind, Placebo-Controlled, Multi-Center Study to Determine the Safety and Effectiveness of Zemplar® (Paricalcitol Injection) in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric End Stage Renal Disease Subjects on Hemodialysis</p> <p>Greenbaum LA, Benador N, Goldstein SL, et al. Intravenous Paricalcitol for Treatment of Secondary Hyperparathyroidism in Children on Hemodialysis. American Journal of Kidney Diseases 2007; 49(6):814-823.</p> <p>Abbott Laboratories (Abbott) will use reasonable efforts to include accurate and up-to-date information, consistent with Abbott policies and procedures, on the ClinicalStudyResults.org web site. However, because, among other reasons, the status of studies often changes, Abbott can make no, and makes no, warranties or representations of any kind as to the currency or completeness of the information contained therein. Persons accessing and using information posted by Abbott on the ClinicalStudyResults.org web site do so at their own risk. Abbott disclaims all warranties, express or implied, including warranties of merchantability of fitness for a particular purpose. Abbott shall not be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of, or inability to use information posted by Abbott on the ClinicalStudyResults.org web site, or any errors or omissions in the content thereof.</p>					
Company Study	No document provided.					